DekaBank Deutsche Girozentrale Has $40,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

DekaBank Deutsche Girozentrale lowered its holdings in shares of Zymeworks Inc. (NYSE:ZYME) by 70.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,843 shares of the company’s stock after selling 9,191 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Zymeworks were worth $40,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Gladius Capital Management LP grew its stake in Zymeworks by 36.5% during the third quarter. Gladius Capital Management LP now owns 3,940 shares of the company’s stock worth $25,000 after purchasing an additional 1,053 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in Zymeworks during the second quarter worth approximately $35,000. Ameritas Investment Partners Inc. acquired a new stake in Zymeworks during the second quarter worth approximately $38,000. Quantbot Technologies LP acquired a new stake in Zymeworks during the first quarter worth approximately $42,000. Finally, Coppell Advisory Solutions LLC acquired a new stake in Zymeworks in the second quarter valued at approximately $48,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Zymeworks Stock Performance

Shares of Zymeworks stock opened at $8.85 on Thursday. Zymeworks Inc. has a 52 week low of $6.01 and a 52 week high of $13.14. The stock has a 50 day moving average price of $10.86 and a two-hundred day moving average price of $9.53. The stock has a market capitalization of $624.54 million, a PE ratio of -5.09 and a beta of 1.14.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.19. Zymeworks had a negative return on equity of 26.20% and a negative net margin of 156.12%. The firm had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $18.32 million. Research analysts forecast that Zymeworks Inc. will post -1.04 EPS for the current year.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.